Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment

People with Alzheimer’s disease will be less likely to receive Aduhelm because of the company’s decision to slash commercial support for the drug in the face of restricted reimbursement by the U.S. Medicare program and other insurers.

People with Alzheimer’s disease will be less likely to receive Aduhelm because of the company’s decision to slash commercial support for the drug in the face of restricted reimbursement by the U.S. Medicare program and other insurers.

Source: Read More

PAID

Leave a Comment